Duncker Streett & Co’s Edwards Lifesciences EW Stock Holding History

Duncker Streett & Co’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$162K	Hold	2,029	–	–	0.03%	248
2025 Q4	$173K	Hold	2,029	–	–	0.03%	240
2025 Q3	$158K	Hold	2,029	–	–	0.03%	249
2025 Q2	$159K	Sell	2,029 -120	-6%	-$8.95K	0.03%	246
2025 Q1	$156K	Sell	2,149 -520	-19%	-$37.2K	0.03%	241
2024 Q4	$198K	Sell	2,669 -140	-5%	-$9.8K	0.04%	225
2024 Q3	$185K	Hold	2,809	–	–	0.03%	238
2024 Q2	$259K	Hold	2,809	–	–	0.05%	204
2024 Q1	$268K	Hold	2,809	–	–	0.05%	201
2023 Q4	$214K	Hold	2,809	–	–	0.05%	206
2023 Q3	$195K	Hold	2,809	–	–	0.05%	209
2023 Q2	$265K	Hold	2,809	–	–	0.06%	190
2023 Q1	$232K	Hold	2,809	–	–	0.06%	197
2022 Q4	$210K	Sell	2,809 -218	-7%	-$16.8K	0.05%	203
2022 Q3	$250K	Hold	3,027	–	–	0.06%	192
2022 Q2	$288K	Hold	3,027	–	–	0.07%	191
2022 Q1	$356K	Sell	3,027 -410	-12%	-$46K	0.07%	189
2021 Q4	$445K	Hold	3,437	–	–	0.08%	186
2021 Q3	$389K	Hold	3,437	–	–	0.07%	187
2021 Q2	$356K	Buy	3,437 +410	+14%	+$38.6K	0.07%	197
2021 Q1	$253K	Hold	3,027	–	–	0.05%	220
2020 Q4	$276K	Hold	3,027	–	–	0.05%	206
2020 Q3	$242K	Hold	3,027	–	–	0.05%	215
2020 Q2	$209K	Sell	3,027 -645	-18%	-$45.8K	0.05%	227
2020 Q1	$231K	Sell	3,672 -1,020	-22%	-$73.6K	0.06%	215
2019 Q4	$365K	Hold	4,692	–	–	0.08%	201
2019 Q3	$344K	Buy	4,692 +900	+24%	+$63.2K	0.08%	208
2019 Q2	$234K	Hold	3,792	–	–	0.05%	243
2019 Q1	$242K	Hold	3,792	–	–	0.06%	243
2018 Q4	$194K	Hold	3,792	–	–	0.05%	245
2018 Q3	$220K	Hold	3,792	–	–	0.05%	253
2018 Q2	$184K	Hold	3,792	–	–	0.05%	264
2018 Q1	$176K	Hold	3,792	–	–	0.04%	265
2017 Q4	$142K	Hold	3,792	–	–	0.04%	289
2017 Q3	$138K	Hold	3,792	–	–	0.04%	276
2017 Q2	$149K	Hold	3,792	–	–	0.05%	270
2017 Q1	$119K	Hold	3,792	–	–	0.04%	295
2016 Q4	$118K	Sell	3,792 -1,050	-22%	-$34K	0.04%	285
2016 Q3	$195K	Buy	4,842 +1,050	+28%	+$39.5K	0.07%	238
2016 Q2	$126K	Buy	3,792 +360	+10%	+$12.3K	0.04%	264
2016 Q1	$101K	Buy	3,432 +132	+4%	+$3.64K	0.04%	279
2015 Q4	$87K	Hold	3,300	–	–	0.03%	303
2015 Q3	$78K	Hold	3,300	–	–	0.03%	319
2015 Q2	$78K	Hold	3,300	–	–	0.03%	332
2015 Q1	$78K	Hold	3,300	–	–	0.03%	332
2014 Q4	$70K	Hold	3,300	–	–	0.02%	349
2014 Q3	$56K	Hold	3,300	–	–	0.02%	363
2014 Q2	$47K	Hold	3,300	–	–	0.02%	392
2014 Q1	$41K	Hold	3,300	–	–	0.01%	390
2013 Q4	$36K	Hold	3,300	–	–	0.01%	393
2013 Q3	$38K	Hold	3,300	–	–	0.02%	369
2013 Q2	$37K	Buy	+3,300	New	+$39.1K	0.01%	376

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Duncker Streett & Co's EW Position: Q1 2026 in Review

Duncker Streett & Co held its Edwards Lifesciences (EW) position steady in Q1 2026 at 2,029 shares worth $162K. The position accounts for 0.03% of the portfolio, ranked #248.

Duncker Streett & Co first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $445K in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Duncker Streett & Co held 2,029 shares of Edwards Lifesciences worth $162K as of Q1 2026.
Duncker Streett & Co left its Edwards Lifesciences share count unchanged in Q1 2026.
Edwards Lifesciences made up 0.03% of Duncker Streett & Co's portfolio in Q1 2026, its #248 holding.
Duncker Streett & Co first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
Duncker Streett & Co's Edwards Lifesciences position peaked at $445K in Q4 2021.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Duncker Streett & Co's 13F filing for Q1 2026, filed 29 Apr 2026.